ACEIs for cardiovascular risk reduction: Have we taken our eye off the ball?

Australian Family Physician

Volumn 42, Issue 8, 2013, Pages 634-638

  Sindone, Andrew ^a   Erlich, Jonathan ^b   Perkovic, Vlado ^c   Suranyi, Michael ^d   Newman, Henry ^d   Lee, Choon ^e   Barin, Edward ^c   Roger, Simon D ^f  

^a ANZAC Research Institute   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

^e NEPEAN HOSPITAL   (Australia)

^f GOSFORD HOSPITAL   (Australia)

Author keywords

Angiotensin receptor antagonists; Angiotensin converting enzyme inhibitors; Cardiovascular diseases; Hypertension; Risk assessment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; HUMAN; HYPERTENSION; RISK ASSESSMENT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RISK ASSESSMENT;

EID: 84884147437     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. National Heart Foundation of Australia. Guide to management of hypertension 2008. Updated December 2010. Available at www.heartfoundation. org.au/SiteCollectionDocuments/ HypertensionGuidelines2008to2010Update.pdf [Accessed 11 February 2013].
2. Australian Institute of Health and Welfare. Living dangerously, Australians with multiple risk factors for cardiovascular disease. AIHW bulletin no. 24. Cat. no. AUS 57. Canberra: AIHW, 2005.
3. National Vascular Disease Prevention Alliance. Absolute cardiovascular disease risk assessment. Quick reference guide for health professionals, 2009. Available at www.cvdcheck.org.au [Accessed 12 September 2012].
4. Medicare Australia. Pharmaceutical Benefits Scheme Item Reports, 2002-12. Available at www.medicareaustralia.gov.au/statistics/pbs_item.shtml [Accessed 16 October 2012].
5. Epstein BJ, Gurns JG. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann Pharmacother 2005;39:470-80.
6. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-54.
7. Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res 2011;34:154-60.
8. Zimmerman D, Burns KD. Angiotensin-(1-7) in kidney disease: a review of the controversies. Clin Sci (Lond) 2012;123:333-46.
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
10. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-88.
11. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012. Available at http:// strokefoundation.com.au [Accessed 11 February 2013].
12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
13. Krum H, Jelinek M, Stewart S, Sindone A, Atherton J. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2011 Available at www.heartfoundation.org.au/ sitecollectiondocuments/chronic_heart_failure_ guidelines_2011.pdf [Accessed 11 February 2013].
14. The CONSENSUS Trial Study Group. Effects of enal-april on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;3161:1429-35.
15. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-87.
16. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
17. Pfeffer MA, McMurray JJ, Velaquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
18. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011;342:d2234.
19. Yusuf S, Teo KK, Pogue J, et al for the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
20. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012;33:2088-97.
21. Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertension 2009;27:941-46.
22. Dahlöf B, Sever PS, Poulter NR, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
23. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors (TRANSCEND): a randomised controlled trial. Lancet 2008;372:1174-83.
24. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828.
25. Ruggenenti P, Fassi A, Ilieva AP, et al for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.
26. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40.
27. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-69.
28. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542-49.
29. Chadban S, Howell M, Twigg S, et al. National evidence based guideline for diagnosis, prevention and management of chronic kidney disease in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC, 2009.
30. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Reducing risk in heart disease: guidelines for preventing cardiovascular events in people with coronary heart disease 2007 (Updated 2008). Available at www.heartfoundation.org.au/SiteCollectionDocuments/ Reduce-risk-in-heart-disease-guideline.pdf [Accessed 11 February 2013].
31. Diabetes Australia. Diabetes management in general practice. 17th edition, 2011/12. Available at www.racgp.org.au/download/documents/Guidelines/Diab etes/201107diabetesmanagementingeneralpractice. pdf [Accessed 11 February 2013].
32. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012. Available at http:// strokefoundation.com.au/health-professionals/ nvdpa-alliance/ [Accessed 11 February 2013].
33. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129:169-73S.
34. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Med J Aust 2008;188:224-27.
35. National Stroke Foundation. Clinical guidelines for stroke management 2010. Melbourne, Australia. Available at http://strokefoundation.com.au/ site/media/clinical_guidelines_stroke_managment_ 2010_interactive.pdf [Accessed 11 February 2013].